Danelle Shaw, APRN
Nurse Practitioner · Scottsbluff, NENPI 1922354141
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Boston Scientific at 34.3% of the total. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $64.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$5K
- Saluda Medical Americas, Inc.$2K
- AbbVie$830
- Pacira Pharmaceuticals Incorporated$708
- Collegium Pharmaceutical, Inc.$367
- plus $1K from 18 others
What the payments were for
- Travel & lodging$8,32556%
- Food & beverage$6,37743%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $5,072 |
| Medtronic | 57 | $4,667 |
| Saluda Medical Americas, Inc. | 4 | $1,923 |
| AbbVie | 36 | $830 |
| Pacira Pharmaceuticals Incorporated | 7 | $708 |
| Collegium Pharmaceutical, Inc. | 19 | $367 |
| Averitas Pharma Inc. | 8 | $200 |
| Lundbeck LLC | 6 | $112 |
| Forte Bio-pharma LLC | 6 | $94 |
| Abbott | 4 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $80 |
| Indivior Inc. | 4 | $75 |
| Vertex | 3 | $69 |
| Biodelivery Sciences International, Inc. | 4 | $67 |
| Azurity Pharmaceuticals, Inc. | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Pfizer | 4 | $59 |
| SPR Therapeutics, Inc | 2 | $57 |
| GRT US Holding, Inc. | 2 | $46 |
| Si-bone, Inc. | 2 | $38 |
| MML US, Inc. | 3 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Nalu Medical, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAVEWRITER ALPHA$2,467
- Evoke$1,838
- Intracept$1,628
- SYNCHROMEDII$1,551
- INTELLIS ADAPTIVESTIM$1,438
- Iovera$561
How this compares
$14,801 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 115 | $83,103 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 336 | $61,870 |
| Buprenorphine | 203 | $46,987 |
| RelistorMethylnaltrexone Bromide | 15 | $35,854 |
| QuliptaAtogepant | 26 | $25,382 |
| UbrelvyUbrogepant | 18 | $18,849 |
| MovantikNaloxegol Oxalate | 43 | $18,785 |
| Emgality PenGalcanezumab-Gnlm | 22 | $16,996 |
| Pregabalin | 501 | $13,491 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,940 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $8,234 |
| Buprenorphine Hcl | 286 | $8,186 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 188 | $6,592 |
| Gabapentin | 446 | $5,583 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $5,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $367 | $83,103115 claims |
| AbbVieQulipta, Ubrelvy | $830 | $44,23144 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $80 | $35,85415 claims |
| Indivior Inc.Suboxone | $75 | $8,23417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Scottsbluff
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
- Lisa OstendorfLincoln$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.